Premium
Rabeprazole‐based therapy in Helicobacter pylori eradication
Author(s) -
Barth J.,
Hahne W.
Publication year - 2002
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.2002.0160s1031.x
Subject(s) - rabeprazole , medicine , helicobacter pylori , helicobacter infections , gastroenterology , helicobacter
Rabeprazole's favourable pharmacodynamic profile is a result of its rapid onset and its 24‐h control of gastric parietal secretion. These qualities, and its antimicrobial properties, make it particularly effective in the treatment of Helicobacter pylori ( H. pylori ), which is a short course of treatment compared to other conditions treated with proton pump inhibitors. Recently completed trials in combination with amoxicillin, clarithromycin and metronidazole for 7 days achieved high eradication of H. pylori . An additional study assessing the efficacy of combined rabeprazole and antibiotic treatments of 3, 7, and 10 days' duration vs. FDA‐approved 10‐day omeprazole triple therapy is under way to address the possibility of shorter duration therapies in the USA.